Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CorMedix Inc.
With the successful launch of Novartis’ Pluvicto and Lutathera, more firms are developing radioligands in the hopes of mitigating side effects and addressing unmet needs in cancer.
Private Company Edition: Sironax completed a $200m series B round while IDRx launched with $122m and OriCell raised $120m in series C funds, joining end-of-July $100m-plus fundraiser Carmot Therapeutics, which closed a $160m series D financing.
Rising leader Mårten Steen, spoke with In Vivo about translating science into business, building precision medicine firms from the ground up and the importance of high-energy leadership.
Private Company Edition: While the tough state of financing for publicly traded drug developers continues, venture capital firms and private biopharma companies revealed billions of dollars in new VC funds and start-up financings, including $100m-plus mega-rounds for Tessa, Alladapt and ImCheck.
- Medical Devices
- Specialty Pharmaceuticals